After ALTTO: I-SPY Will Hold More Clues About pCR Surrogate Endpoint
The pathological complete response surrogate marker has been hailed as the key to getting drugs to market faster with small studies, but came under attack at ASCO with the failed ALTTO breast cancer trial. Co-lead I-SPY investigator Laura Esserman takes a critical look at ALTTO and explains why the jury is still out on pCR; story features an audio clip of Esserman’s interview with “The Pink Sheet.”
You may also be interested in...
Five neoadjuvant breast cancer regimens have been tested successfully in I-SPY Phase II program, but three have not moved on to sponsor-driven pivotal testing and the I-SPY 3 master protocol has yet to be used.
Roche’s key HER2 breast cancer franchise boasted a stellar sales performance in the first-quarter – rising 27% in the U.S. alone – and the rest of the cancer business followed suit. But, the loss of schizophrenia candidate bitopertin casts a shadow on the firm’s plans for neuroscience.
I-SPY 2 investigators are buoyed by “strong signal” for neratinib in high-risk subgroup in adaptive design study. Investors, however, are underwhelmed by results.